Her2 low metastatic breast cancer, new therapy from AstraZeneca and Daiichi Sankyo

The Italian Medicines Agency has given the green light to the reimbursement of trastuzumab deruxtecan, the monoclonal antibody drug-conjugate from Daiichi Sankyo and AstraZeneca, for the treatment of patients with metastatic breast cancer and low expression of the HER2 protein (HER2 low) . The new therapeutic option substantially improves both progression-free survival and overall survival.